Cochrane Evidence Synthesis and Methods ►

Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

Primary objective

To evaluate the relative benefits and harms of therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose co-transporter-2 inhibitors (SGLT2i), and their combination in adults with type 2 diabetes mellitus.

Secondary objectives

To determine the relative rankings of GLP-1RA, SGLT2i, and their combination, according to their comparative efficacy for the critical outcomes identified in this review through a network meta-analysis.

This is a protocol.

Published:

16 April 2025

Authors:

Osman AAM, Tayeb BA, Metzendorf MI, Bongaerts B, Mohammed N, Njangiru IK, Franco JVA

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Osman AAM, Tayeb BA, Metzendorf MI, Bongaerts B, Mohammed N, Njangiru IK, Franco JVA. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis (Protocol). Cochrane Database of Systematic Reviews 2025, Issue 4. Art. No.: CD015952. DOI: 10.1002/14651858.CD015952.